Intuitive Surgical Zooms Higher After Da Vinci Helps Smash Forecasts

Core Insights - Intuitive Surgical's new robotic surgery system, da Vinci 5, is gaining traction, contributing to significant stock price increases and strong earnings reports [1][3][4] Financial Performance - Intuitive Surgical reported third-quarter sales of $2.51 billion, a 23% increase year-over-year, surpassing expectations of $2.41 billion [6] - The company achieved an adjusted earnings per share of $2.40, exceeding analysts' forecasts of $1.99 [6] - Instrument and accessory sales reached $1.52 billion, growing 20% due to strong procedure growth [5] Procedure Growth - Worldwide procedure growth was reported at 20%, with da Vinci systems contributing 19% and Ion systems, which perform lung biopsies, contributing 52% [4] - The company now expects procedure growth for the year to be between 17% and 17.5%, compared to last year's growth of 17% [5] - Analysts had initially projected a lower procedure growth of 15.8% [5] Da Vinci System Installations - In the third quarter, Intuitive Surgical installed 427 new da Vinci systems, including 240 of the da Vinci 5, compared to 379 and 110 installations in the same period last year [7] - The company also placed 50 Ion systems, a slight decrease from 58 in the previous year [7] Market Sentiment - Analysts maintain a positive outlook on Intuitive Surgical, with some noting potential concerns regarding procedure pull-forward in the U.S. and international capital expenditure weaknesses [8] - Overall, the third-quarter results are viewed as a strong endorsement of durable growth trends in the robotic surgery market [9]